The phase 2b SYMMETRY trial, a multicenter, randomized, double-blind, placebo-controlled study, included 181 patients with compensated cirrhosis (Child-Pugh A) due to MASH (78% with histological diagnosis and 22% with cryptogenic cirrhosis attributed to MASH) assigned to receive efruxifermin at doses of 28 or 50 mg, or placebo (1:1:1), for 96 weeks
Pinnacle Peptides supplies Epithalon at 10mg per vial, synthesised in the USA and verified at 99%+ purity by HPLC and Mass Spectrometry
This is a full syringe
Capsule (Hydroxypropyl Methylcellulose, Colour (Brilliant Blue)), Anti-Caking Agents (Silicon Dioxide, Magnesium Stearate)
This is why I want you asking: Is this intended as a long-term medication for me
[PubMed] [Google Scholar] 74.Klicek R., Kolenc D., Suran J., Drmic D., Brcic L., Aralica G., Sever M., Holjevac J., Radic B., Turudic T., et al